We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+12.52%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$427M
AUM Growth
+$187M
Cap. Flow
+$161M
Cap. Flow %
37.84%
Top 10 Hldgs %
59.81%
Holding
55
New
16
Increased
13
Reduced
16
Closed
8

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.3M
2
CRL icon
Charles River Laboratories
CRL
+$5.97M
3
EW icon
Edwards Lifesciences
EW
+$5.88M
4
BAX icon
Baxter International
BAX
+$5.29M
5
AVTR icon
Avantor
AVTR
+$5.09M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$6.88M
2
MDT icon
Medtronic
MDT
+$6.59M
3
THC icon
Tenet Healthcare
THC
+$6.29M
4
ZBH icon
Zimmer Biomet
ZBH
+$6.08M
5
DVA icon
DaVita
DVA
+$4.71M

Sector Composition

Rank Sector Weight
1 Healthcare 57.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
51
Medtronic
MDT
$116B
– –
-80,000
Closed -$6.59M
QGEN icon
52
Qiagen
QGEN
$8.88B
– –
-51,868
Closed -$2.39M
WBA
53
DELISTED
Walgreens Boots Alliance
WBA
– –
-90,000
Closed -$2.35M
ZBH icon
54
Zimmer Biomet
ZBH
$18.7B
– –
-50,000
Closed -$6.08M
1 2
3

Similar funds

AFP
ATX Financial Planning Austin, Texas $132M AUM
PCGDR
Pangea Capital Gestao de Recursos Rio De Janeiro $131M AUM
ACM
Alcosta Capital Management San Ramon, California $131M AUM 34.7% 1-Year Est. Return
9C
9823 Capital Dallas, Texas $132M AUM
STFP
Signal Tree Financial Partners Copley, Ohio $132M AUM 15.43% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $131M AUM 7.53% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return
CIP
Castlefield Investment Partners Manchester $131M AUM

Sivik Global Healthcare's Q1 2024 Portfolio in Review

As of Q1 2024, Sivik Global Healthcare held 55 positions worth $427M, up 78% from $239M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sivik Global Healthcare deployed $161M of net new capital in Q1 2024, opening 16 new positions and adding to 13 existing holdings. Its largest new stake was Charles River Laboratories: 25,000 shares worth $6.77M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was HCA Healthcare, an estimated $6.88M trimmed.

  • Sivik Global Healthcare's largest Q1 2024 buy was Charles River Laboratories: 25,000 shares worth $6.77M.
  • Sivik Global Healthcare added most to State Street SPDR S&P Biotech ETF in Q1 2024, an estimated $15.3M increase.
  • Sivik Global Healthcare's biggest Q1 2024 reduction was HCA Healthcare, cutting an estimated $6.88M.
  • Sivik Global Healthcare fully exited Medtronic in Q1 2024, selling an estimated $6.59M.
  • Sivik Global Healthcare's ten largest holdings make up 60% of its $427M portfolio in Q1 2024.
  • Sivik Global Healthcare opened 16 new positions and closed 8 in Q1 2024.
  • Sivik Global Healthcare's portfolio value rose 78% quarter-over-quarter to $427M.

Based on Sivik Global Healthcare's 13F filing for Q1 2024, filed 1 May 2024.